ORIGINAL ARTICLE

Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade

J L Xu¹, R Lai³, T Kinoshita², N Nakashima¹ and T Nagasaka¹

¹ Department of Laboratory Medicine, Nagoya University School of Medicine, Tsurumai-cho 65, Showa-ku Nagoya 466-8560, Japan
² Department of Internal Medicine, Nagoya University School of Medicine
³ Department of Hematopathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas TX77025, USA

Correspondence to:
Correspondence:
Dr T Nagasaka, Division of Pathology, Clinical Laboratory, Nagoya University Hospital, Tsurumai-cho 65, Showa-ku, Nagoya 466–8560, Japan;
nagat{at}med.nagoya-u.ac.jp

Aims: Abnormalities involving proliferation, apoptosis, and angiogenesis are important in tumorigenesis. The purpose of this study was to examine these three biological processes, and their relation with the clinical stage and cytological grade in multiple myeloma (MM).

Methods: Fifty four newly diagnosed patients with MM were studied by immunohistochemistry using bone marrow clot sections. Proliferation and apoptosis were evaluated for the proportion of MM cells (indicated by morphology and CD138 reactivity) positive for the Ki67 antigen and single stranded DNA (ssDNA), respectively. Angiogenesis was evaluated by measuring the intratumoral microvessel density (IMVD) and by assessing the immunoreactivity of vascular endothelial growth factor (VEGF).

Results: There were 30 men and 24 women (median age, 65 years; range, 37–84). At initial presentation, 15 (28%) were in Durie stage I, 15 (28%) in stage II, and 24 (44%) in stage III. Advanced clinical stage correlated with high cytological grade (p < 0.03). The medians for Ki67, ssDNA, and IMVD were 4.4% (range, 0–15%), 0.2% (range, 0–2.8%), and 15.5 (range, 0–63), respectively. Among these three continuous parameters, the only significant correlation was that between Ki67 and IMVD (p < 0.0001). Both Ki67 and IMVD also correlated with the clinical stage, cytological grade, and VEGF positivity (p <0.05). No correlation was found between ssDNA and all of the other parameters.

Conclusions: These data suggest that proliferation is associated with angiogenesis in MM. Furthermore, proliferation and angiogenesis, but not apoptosis, may be important in disease progression. Lastly, increased production of VEGF may be one of the contributing factors to the increase in intratumoral vascularity seen in advanced MM.

Keywords: multiple myeloma; proliferation; apoptosis; angiogenesis; clinical stage; cytological grade

Abbreviations: IL, interleukin; IMVD, intratumoral microvessel density; MM, multiple myeloma; ssDNA, single stranded DNA; VEGF, vascular endothelial growth factor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Colla, S., Tagliaferri, S., Morandi, F., Lunghi, P., Donofrio, G., Martorana, D., Mancini, C., Lazzaretti, M., Mazzera, L., Ravanetti, L., Bonomini, S., Ferrari, L., Miranda, C., Ladetto, M., Neri, T. M., Neri, A., Greco, A., Mangoni, M., Bonati, A., Rizzoli, V., Giuliani, N. (2007). The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angiogenesis. Blood 110: 4464-4475 [Abstract] [Full Text]  
• Xu, J., Nagata, K., Obata, K., Ichihara, S., Izawa, H., Noda, A., Nagasaka, T., Iwase, M., Naoe, T., Murohara, T., Yokota, M. (2005). Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats. Hypertension 46: 719-724 [Abstract] [Full Text]  
• Van Valckenborgh, E., Croucher, P. I., De Raeve, H., Carron, C., De Leenheer, E., Blacher, S., Devy, L., Noel, A., De Bruyne, E., Asosingh, K., Van Riet, I., Van Camp, B., Vanderkerken, K. (2004). Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma: A Study in the 5T2MM Mouse Model. Am. J. Pathol. 165: 869-878 [Abstract] [Full Text]  
• Hideshima, T., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C. (2004). Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618 [Abstract] [Full Text]  
• Asosingh, K., De Raeve, H., Menu, E., Van Riet, I., Van Marck, E., Van Camp, B., Vanderkerken, K. (2004). Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 103: 3131-3137 [Abstract] [Full Text]  
• Zangari, M., Anaissie, E., Stopeck, A., Morimoto, A., Tan, N., Lancet, J., Cooper, M., Hannah, A., Garcia-Manero, G., Faderl, S., Kantarjian, H., Cherrington, J., Albitar, M., Giles, F. J. (2004). Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma. Clin. Cancer Res. 10: 88-95 [Abstract] [Full Text]  
• London, C. A., Hannah, A. L., Zadovoskaya, R., Chien, M. B., Kollias-Baker, C., Rosenberg, M., Downing, S., Post, G., Boucher, J., Shenoy, N., Mendel, D. B., McMahon, G., Cherrington, J. M. (2003). Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies. Clin. Cancer Res. 9: 2755-2768 [Abstract] [Full Text]